Assessment of pathogenic variation in gynecologic cancer genes in a national cohort

Sci Rep. 2023 Mar 31;13(1):5307. doi: 10.1038/s41598-023-32397-8.

Abstract

Population-based estimates of pathogenic variation burden in gynecologic cancer predisposition genes are a prerequisite for the development of effective precision public health strategies. This study aims to reveal the burden of pathogenic variants in a comprehensive set of clinically relevant breast, ovarian, and endometrial cancer genes in a large population-based study. We performed a rigorous manual classification procedure to identify pathogenic variants in a panel of 17 gynecologic cancer predisposition genes in a cohort of 7091 individuals, representing 0.35% of the general population. The population burden of pathogenic variants in hereditary gynecologic cancer-related genes in our study was 2.14%. Pathogenic variants in genes ATM, BRCA1, and CDH1 are significantly enriched and the burden of pathogenic variants in CHEK2 is decreased in our population compared to the control population. We have identified a high burden of pathogenic variants in several gynecologic cancer-related genes in the Slovenian population, most importantly in the BRCA1 gene.

MeSH terms

  • Breast Neoplasms* / genetics
  • Female
  • Genes, BRCA1
  • Genetic Predisposition to Disease
  • Genital Neoplasms, Female* / genetics
  • Germ-Line Mutation
  • Hereditary Breast and Ovarian Cancer Syndrome* / genetics
  • Humans
  • Oncogenes
  • Ovarian Neoplasms* / genetics